Barry Effron, MD
Watch to find out more about this University Hospitals physician.
Director, Evaluation and Prevention Center, UH Cleveland Medical Center
Associate Professor, Medicine, CWRU School of Medicine
UH Cleveland Medical Center
Department of Medicine-Cardiovascular Medicine
11100 Euclid Ave
UH Chagrin Highlands Health Center
3909 Orange Pl
Harrington Heart and Vascular Institute, Ste 3300
Cardiomyopathy, Cardiology, Lipid Management, Preventive Cardiovascular Medicine, Coronary Artery Disease (CAD), Valvular Heart Disease
American Board of Internal Medicine - Cardiovascular Disease
American Board of Internal Medicine - Internal Medicine
Education & Training
1975, Cornell University
Medical / Professional School(s):
1978, The Ohio State University College of Medicine
1979, Internal Medicine - OHIO STATE UNIVERSITY HOSPITAL
1980, Internal Medicine - OHIO STATE UNIVERSITY HOSPITAL
1981, Internal Medicine - University Hospitals of Cleveland
1984, Internal Medicine/Chief Resident - University Hospitals of Cleveland
1983, Cardiovascular Disease - University Hospitals of Cleveland
1985, Cardiovascular Disease - University of Wisconsin-Madison
Patient Satisfaction Reviews
About Our Survey
At University Hospitals, we believe in providing patients with all the information they need to make educated decisions about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians. We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for every individual who sees a UH doctor.
There are no comments for this practitioner.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Barry Effron, MD disclosed the following Outside Relationships with Industry:
Boehringer Ingelheim Pharmaceutical, Inc. (BIPI) - Consulting
Amgen, Inc. - Honoraria